Advertisement

Prodrugs pp 339-355 | Cite as

Prodrugs to Reduce Presystemic Metabolism

  • Bruce J. Aungst
  • Nicole Matz
Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume V)

Abstract

One of the most important pharmacokinetic characteristics of a drug or new drug candidate is its oral bioavailability. The oral route is the preferred means of administration for most drug therapies, particularly those self-administered by the patient on an ongoing basis. Unless a drug is intended to treat a condition of the gastrointestinal tract, its effectiveness after oral administration requires attaining adequate and consistent systemic exposure. The extent of bioavailability determines the levels of exposure as well as the variability in exposure. Hellriegel et al. (1996) surveyed 143 literature references reporting absolute oral bioavailability and described the relationship between absolute bioavailability and inter-subject variability (% CV) for 100 drugs studied in those references. It was shown that the variability of systemic exposure after oral dosing was greatest when oral bioavailability was low and, conversely, inter-subject variability was generally low when oral bioavailability was high. Variability of systemic exposure leads to inconsistent and possibly unpredictable pharmacological and toxicological effects of the drug. Therefore, drugs with good oral bioavailability can have a considerable therapeutic advantage over related drugs with poor oral bioavailability.

Keywords

Oral Bioavailability Salmon Calcitonin Ester Prodrug Presystemic Metabolism Phenyl Carbamate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anderson BD, Chu WW, and Galinsky RE. Reduction of First-pass Metabolism of Propranolol after Oral Administration of Ester Prodrugs. Int J Pharm 1988; 43:261–265CrossRefGoogle Scholar
  2. Aungst BJ, Myers MJ, Shefter E, and Shami EG. Prodrugs for Improved Oral Nalbuphine Bioavailability: Inter-species Differences in the Disposition of Nalbuphine and its Acetylsalicylate and Anthranilate Esters. Int J Pharm 1987; 38:199–209CrossRefGoogle Scholar
  3. Boswell GA, and Myers MJ. N-oxide Prodrug Derivatives of 3-hydroxy morphinans and Partial Morphinans having Improved Oral Bioavailability, Pharmaceutical Compositions, and Processes. U.S. Patent # 4,722,928, 1985.Google Scholar
  4. Bundgaard H and Rasmussen G. Prodrugs of Peptides. 9. Bioreversible N-alphahydroxylation of the Peptide Bond to Effect Protection Against Carboxypeptidase or Other Proteolytic Enzymes. Pharm Res 1991; 8:313–322PubMedCrossRefGoogle Scholar
  5. Buyse G, Waldeck K, Verpoorten C, Bjork H, Casaer P, and Andersson KE. Intravesical Oxybutynin for Neurogenic Bladder Dysfunction: Less Systemic Side Effects due to Reduced First Pass Metabolism. J Urol 1998; 160:892–896.PubMedCrossRefGoogle Scholar
  6. Clarke A, Brewer F, Johnson ES, Mallard N, Hartig F, Taylor S, and Corn TH. A New Formulation of Selegiline: Improved Bioavailability and Selectivity for MAO-B Inhibition. J Neural Transm 2003; 110:1241–1255.PubMedCrossRefGoogle Scholar
  7. D’Souza MD, Venkataramanan R, D’Mello A, and Niphadkar P. An Alternative Prodrug Approach for Reducing Presystemic Metabolism of Drugs. Int J Pharm 1986; 31:165–167CrossRefGoogle Scholar
  8. Elger W, Schwarz S, Hedden A, Reddersen G, and Schneider B. Sulfamates of Various Estrogens are Prodrugs with Increased Systemic and Reduced Hepatic Estrogenicity at Oral Application. J Steroid Biochem Mol Biol 1995; 55:395–403PubMedCrossRefGoogle Scholar
  9. Eriksson UG, Bredberg U, Hoffmann K-J, Thuresson A, Gabrielsson M, Ericsson H, Ahnoff M, Gislen K, Fager G, and Gustafsson D. Absorption, Distribution, Metabolism, and Excretion of Ximelagatran, an Oral Direct Thrombin Inhibitor, in Rats, Dogs, and Humans. Drug Metab Disp 2003; 31:294–305CrossRefGoogle Scholar
  10. Garceau Y, Davis I, and Hasegawa J. Plasma Propranolol Levels in Beagle Dogs after Administration of Propranolol Hemisuccinate Ester. J Pharm Sci 1978; 67:1360–1363PubMedCrossRefGoogle Scholar
  11. Gudmundsson OS, Pauletti GM, Wang W, Shan D, Zhang H, Wang B, and Borchardt RT. Coumarinic Acid-Based Cyclic Prodrugs of Opioid Peptides that Exhibit Metabolic Stability to Peptidases and Excellent Cellular Permeability. Pharm Res 1999; 16:7–15PubMedCrossRefGoogle Scholar
  12. Gudmundsson OS, Nimkar K, Gangwar S, Siahaan T, and Borchardt RT. Phenylpropionic Acid-Based Cyclic Prodrugs of Opioid Peptides that Exhibit Metabolic Stability to Peptidases and Excellent Cellular Permeability. Pharm Res 1999; 16:16–23PubMedCrossRefGoogle Scholar
  13. Hansen J, Mork N, and Bundgaard H. Phenyl Carbamates of Amino Acids as Prodrug Forms for Protecting Phenols against First-pass Metabolism. Int J Pharm 1992; 81:253–261CrossRefGoogle Scholar
  14. Hellriegel ET, Bjornsson TD, and Hauck WW. Interpatient Variability in Bioavailability is Related to the Extent of Absorption: Implications for Bioavailability and Bioequivalence Studies. Clin Pharmacol Ther 1996; 60:601–607PubMedCrossRefGoogle Scholar
  15. Holstein-Rathou N-H, Laursen LC, Madsen F, Svendsen UG, Gnosspelius Y, and Weeke B. Bambuterol: Dose Response Study of a New Terbutaline Prodrug in Asthma. Eur J Clin Pharmacol 1986; 30:7–11CrossRefGoogle Scholar
  16. Hussain MA, Koval CA, Myers MJ, Shami EG, and Shefter E. Improvement of the Oral Bioavailability of Naltrexone in Dogs: a Prodrug Approach. J Pharm Sci 1987; 76:356–358PubMedCrossRefGoogle Scholar
  17. Hussain MA, Aungst BJ, and Shefter E. Prodrugs for Improved Oral Betaestradiol Bioavailability. Pharm Res 1988; 5:44–47PubMedCrossRefGoogle Scholar
  18. Hussain MA and Shefter E. Naltrexone-3-salicylate (a Prodrug of Naltrexone): Synthesis and Pharmacokinetics in Dogs. Pharm Res 1988; 5:113–115PubMedCrossRefGoogle Scholar
  19. Kahns AH and Bundgaard H. Prodrugs of Peptides. 13. Stabilization of Peptide Amides Against Alpha-chymotrypsin by the Prodrug Approach. Pharm Res 1991; 8:1533–1538PubMedCrossRefGoogle Scholar
  20. Kahns AH, Buur A, and Bundgaard H. Prodrugs of Peptides. 18. Synthesis and Evaluation of Various Esters of Desmopressin (dDAVP). Pharm Res 1993; 10:68–74PubMedCrossRefGoogle Scholar
  21. Murata K, Noda K, Kohno K, and Samejima M. Bioavailability and Pharmacokinetics of an Oral Dopamine Prodrug in Dogs. J Pharm Sci 1989; 78:812–814PubMedCrossRefGoogle Scholar
  22. Na DH, Youn YS, Park EJ Lee JM, Cho OR, Lee KR, Lee SD, Yoo SD, DeLuca PP, and Lee KC. Stability of PEGylated Salmon Calcitonin in Nasal Mucosa. J. Pharm. Sci. 2004; 93:256–261PubMedCrossRefGoogle Scholar
  23. Obermeier MT, Chong S, Dando SA, Marino AM, Ryono DE, Starrett-Arroyo A, DiDonato GC, Warrack BM, White RE, and Morrison RA. Prodrugs of BMS-183920: Metabolism and Permeability Considerations. J Pharm Sci 1996; 85:828–833PubMedCrossRefGoogle Scholar
  24. Patel J, Katovich MJ, Sloan KB, Curry SH, and Prankerd RJ. A Prodrug Approach to Increasing the Oral Potency of a Phenolic Drug. Part 2. Pharmacodynamics and Preliminary Bioavailability of an Orally Administered O-(imidomethyl) Derivative of 17 beta-Estradiol. J Pharm Sci 1995; 84:174–178PubMedCrossRefGoogle Scholar
  25. Shameem M, Imai T, and Otagiri M. An In-vitro and In-vivo Correlative Approach to the Evaluation of Ester Prodrugs to Improve Oral Delivery of Propranolol. J Pharm Pharmacol 1993; 45:246–252PubMedGoogle Scholar
  26. Thomsen KF and Bundgaard H. Cyclization-activated Phenyl Carbamate Prodrug Forms for Protecting Phenols Against First-pass Metabolism. Int J Pharm 1993; 91:39–49.CrossRefGoogle Scholar
  27. Vickers S, Duncan CA, D, Breault GO, Royds RB, De Schepper PJ, and Tempero KF. Evaluation of Succinimidoethyl and Pivaloyloxyethyl Esters as Progenitors of Methyldopa in Man, Rhesus Monkey, Dog, and Rat. Drug Metab Disp 1978; 6:640–646Google Scholar
  28. Vickers S, Duncan CAH, Ramjit HG, Dobrinska MR, Dollery CT, Gomez HJ, Leidy HL, and Vincek WC. Metabolism of Methyldopa in Man after Oral Administration of the Pivaloyloxyethyl Ester. Drug Metab Disp 1984; 12:242–246Google Scholar
  29. Yodoya E, Uemura K, Tenma T, Fujita T, Murakami M, Yamamoto A, and Muranishi S. Enhanced Permeability of Tetragastrin across the Rat Intestinal Membrane and its reduced Degradation by Acylation with Various Fatty Acids. J Pharmacol Exp Ther 1994; 1509–1513Google Scholar
  30. Yoshigae Y, Imai T, Horita A, Matsukane H, and Otagiri M. Species Differences in Stereoselective Hydrolase Activity in Intestinal Mucosa. Pharm Res 1998a; 15:626–631PubMedCrossRefGoogle Scholar
  31. Yoshigae Y, Imai T, Aso T, and Otagiri M. Species Differences in the Disposition of Propranolol Prodrugs Derived from Hydrolase Activity in the Intestinal Mucosa. Life Sci. 1998b; 62:1231–1241PubMedCrossRefGoogle Scholar
  32. Yoshikawa M, Nishiyama S, Endo H, Togo Y, and Takaiti O. First Pass Metabolism and In Vitro Metabolism of a New Orally Active Dopamine Prodrug, N-(N-acetyl-L-methionyl)O,O-bis(ethoxycarbonyl)dopamine in Dogs. Drug Metab Disp 1991; 19:960–965.Google Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2007

Authors and Affiliations

  • Bruce J. Aungst
    • 1
  • Nicole Matz
    • 1
  1. 1.Quest Pharmaceutical ServicesNewark

Personalised recommendations